{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:57:52Z","timestamp":1761868672603,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2017YFA0105704"],"award-info":[{"award-number":["2017YFA0105704"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2021ZDLSF02-07"],"award-info":[{"award-number":["2021ZDLSF02-07"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81820108005","81900502"],"award-info":[{"award-number":["81820108005","81900502"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Science Bulletin"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.scib.2022.11.029","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T20:40:43Z","timestamp":1669840843000},"page":"2498-2501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Primary biliary cholangitis: personalized medicine for optimal therapeutic opportunities"],"prefix":"10.1016","volume":"67","author":[{"given":"Yulong","family":"Shang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick S.C.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Eric","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.scib.2022.11.029_b0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.scib.2022.11.029_b0010","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.32405","article-title":"Mechanisms and molecules: what are the treatment targets for primary biliary cholangitis?","volume":"76","author":"Mayo","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2022.11.029_b0015","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41423-022-00904-y","article-title":"Treatment with a JAK1\/2 inhibitor ameliorates murine autoimmune cholangitis induced by IFN overexpression","volume":"19","author":"Shao","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.scib.2022.11.029_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102897","article-title":"Dual B-cell targeting therapy ameliorates autoimmune cholangitis","volume":"132","author":"Zhang","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.scib.2022.11.029_b0025","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/hep4.1907","article-title":"Immunoglobulin M: a neglected serum biomarker in treatment-naive primary biliary cholangitis with normal alkaline phosphatase","volume":"6","author":"Ding","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.scib.2022.11.029_b0030","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jhep.2021.04.055","article-title":"An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs","volume":"75","author":"Cordell","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2022.11.029_b0035","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2022.08.054","article-title":"Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls","volume":"163","author":"Murillo Perez","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.scib.2022.11.029_b0040","article-title":"UK-wide multicenter evaluation of second-line therapies in primary biliary cholangitis","author":"Abbas","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.scib.2022.11.029_b0045","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/liv.15386","article-title":"Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid","volume":"42","author":"De Vincentis","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.scib.2022.11.029_b0050","doi-asserted-by":"crossref","DOI":"10.1002\/hep4.2103","article-title":"Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid","author":"Ding","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.scib.2022.11.029_b0055","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/hep.32172","article-title":"E. coli and the etiology of human PBC: antimitochondrial antibodies and spreading determinants","volume":"75","author":"Yang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2022.11.029_b0060","article-title":"Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion","author":"Yang","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.scib.2022.11.029_b0065","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/hep.31810","article-title":"Accuracy of transient elastography in assessing fibrosis at diagnosis in na\u00efve patients with primary biliary cholangitis: a dual cut-off approach","volume":"74","author":"Cristoferi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2022.11.029_b0070","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","volume":"77","author":"Corpechot","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2022.11.029_b0075","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1002\/hep.32011","article-title":"The serum proteome and ursodeoxycholic acid response in primary biliary cholangitis","volume":"74","author":"Barron-Millar","year":"2021","journal-title":"Hepatology"}],"container-title":["Science Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927322005552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927322005552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:53:02Z","timestamp":1761868382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095927322005552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":15,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2095927322005552"],"URL":"https:\/\/doi.org\/10.1016\/j.scib.2022.11.029","relation":{},"ISSN":["2095-9273"],"issn-type":[{"type":"print","value":"2095-9273"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary biliary cholangitis: personalized medicine for optimal therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Science Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.scib.2022.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Science China Press. Published by Elsevier B.V. and Science China Press.","name":"copyright","label":"Copyright"}]}}